Update
$Kintara Therapeutics (KTRA.US)$ Kintara Therapeutics Provides Update On REM-001 Clinical Study, Has Enrolled 4 Of The 10 Patients Needed To Reach The Minimum Patient Enrollment To Assess Safety And Appropriate Phase 3 Dose With Several Other Patients Identified As Study Candidates At Kintara's Clinical Sites, No Treatment-Related Safety Issues Have Been Identified To-Date, And Assessment Of The Appropriate Phase 3 Dose Is Ongoing
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
